IE 11 is a very old Browser and it`s not supported on this site

Performance / Multi-year comparison

Indexed performance since launch (in CHF)

BB Biotech AG (SIX)-CHF
BB BIOTECH AG (XETRA)-EUR
BB BIOTECH AG (MILAN)-EUR
BB Biotech AG (SIX)-CHF
BB BIOTECH AG (XETRA)-EUR
BB BIOTECH AG (MILAN)-EUR

Platzhaltergrafik

Created with Highcharts 8.2.0in %Chart title19941996199820002002200420062008201020122014201620182020202205001000150020002500300035004000

NAV CHF indexed
Share price CHF indexed
Nasdaq Biotech Index (NBI) indexed

Rolling performance

XLS

 

 

SHARE

 

NAV

 

NBI TR

30.09.2020 – 30.09.2021

 

31.1%

 

24.5%

 

21.9%

30.09.2019 – 30.09.2020

 

15.9%

 

21.0%

 

26.4%

30.09.2018 – 30.09.2019

 

(10.6%)

 

(14.1%)

 

(16.2%)

28.09.2017 – 28.09.2018

 

15.6%

 

1.0%

 

12.1%

29.09.2016 – 29.09.2017

 

35.8%

 

29.9%

 

17.6%

Annual performance

XLS

 

 

SHARE

 

NAV

 

NBI TR

2020

 

19.3%

 

24.3%

 

15.8%

2019

 

18.5%

 

23.4%

 

23.0%

2018

 

(5.2%)

 

(14.5%)

 

(8.0%)

2017

 

22.9%

 

23.4%

 

16.4%

2016

 

0.2%

 

(19.3%)

 

(20.0%)

Cumulated performance

30.09.2021

XLS

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

18.2%

 

3.2%

 

13.3%

1 year

 

31.1%

 

24.5%

 

21.9%

3 years

 

35.8%

 

29.4%

 

29.1%

5 years

 

115.1%

 

65.7%

 

65.9%

since inception 1)

 

3 384%

 

2 672%

 

1 547%

1 09.11.1993

Annualized performance

30.09.2021

XLS

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

31.1%

 

24.5%

 

21.9%

3 years

 

10.7%

 

8.9%

 

8.9%

5 years

 

16.5%

 

10.6%

 

10.6%

since inception 1)

 

13.6%

 

12.6%

 

10.6%

1 09.11.1993

Platzhaltergrafik

Created with Highcharts 8.2.0in %Chart title1998200020022004200620082010201220142016201820200500100015002000250030003500

NAV CHF indexed
Share price CHF indexed
Nasdaq Biotech Index (NBI) indexed

Rolling performance

XLS

 

 

SHARE

 

NAV

 

NBI TR

30.09.2020 – 30.09.2021

 

29.6%

 

24.5%

 

21.8%

30.09.2019 – 30.09.2020

 

17.5%

 

22.0%

 

27.3%

30.09.2018 – 30.09.2019

 

(5.8%)

 

(10.0%)

 

(12.6%)

28.09.2017 – 28.09.2018

 

15.4%

 

1.3%

 

13.0%

29.09.2016 – 29.09.2017

 

28.5%

 

23.0%

 

11.5%

Annual performance

XLS

 

 

SHARE

 

NAV

 

NBI TR

2020

 

18.1%

 

24.8%

 

16.1%

2019

 

23.4%

 

28.1%

 

27.6%

2018

 

(2.2%)

 

(11.1%)

 

(4.3%)

2017

 

12.9%

 

12.5%

 

6.7%

2016

 

1.7%

 

(17.8%)

 

(19.0%)

Cumulated performance

30.09.2021

XLS

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

18.9%

 

3.5%

 

13.5%

1 year

 

29.6%

 

24.5%

 

21.8%

3 years

 

43.4%

 

36.8%

 

35.5%

5 years

 

115.9%

 

67.7%

 

67.5%

since inception 1)

 

2 687%

 

2 132%

 

1 502%

1 10.12.1997

Annualized performance

30.09.2021

XLS

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

29.6%

 

24.5%

 

21.8%

3 years

 

12.7%

 

11.0%

 

10.6%

5 years

 

16.6%

 

10.9%

 

10.9%

since inception 1)

 

15.0%

 

13.9%

 

12.3%

1 10.12.1997

Platzhaltergrafik

Created with Highcharts 8.2.0in %Chart title20022004200620082010201220142016201820200100200300400500600700800

NAV EUR indexed
Share Price EUR indexed
Nasdaq Biotech Index (NBI) indexed

Rolling performance

XLS

 

 

SHARE

 

NAV

 

NBI TR

30.09.2020 – 30.09.2021

 

30.6%

 

24.5%

 

21.8%

30.09.2019 – 30.09.2020

 

17.2%

 

22.0%

 

27.3%

30.09.2018 – 30.09.2019

 

(6.3%)

 

(10.0%)

 

(12.6%)

28.09.2017 – 28.09.2018

 

16.6%

 

1.3%

 

13.0%

29.09.2016 – 29.09.2017

 

28.3%

 

23.0%

 

11.5%

Annual performance

XLS

 

 

SHARE

 

NAV

 

NBI TR

2020

 

19.7%

 

24.8%

 

16.1%

2019

 

22.6%

 

28.1%

 

27.6%

2018

 

(1.3%)

 

(11.1%)

 

(4.3%)

2017

 

12.2%

 

12.5%

 

6.7%

2016

 

1.2%

 

(17.8%)

 

(19.0%)

Cumulated performance

30.09.2021

XLS

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

18.4%

 

3.5%

 

13.5%

1 year

 

30.6%

 

24.5%

 

21.8%

3 years

 

43.4%

 

36.8%

 

35.5%

5 years

 

115.4%

 

67.7%

 

67.5%

since inception 1)

 

546%

 

415%

 

214%

1 19.10.2000

Annualized performance

30.09.2021

XLS

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

30.6%

 

24.5%

 

21.8%

3 years

 

12.7%

 

11.0%

 

10.6%

5 years

 

16.6%

 

10.9%

 

10.9%

since inception 1)

 

9.3%

 

8.1%

 

5.6%

1 19.10.2000

Multi-year comparison

XLS

 

 

30.09.2021

 

2020

 

2019

 

2018

 

2017

 

 

Market capitalization at the end of the period (in CHF mn)

 

4 661.9

 

4 107.9

 

3 670.3

 

3 235.4

 

3 576.1

 

toggle chart

Net Asset Value at the end of the period (in CHF mn)

 

3 833.2

 

3 887.5

 

3 393.0

 

2 884.5

 

3 538.7

 

toggle chart

Number of shares (in mn)

 

55.4

 

55.4

 

55.4

 

55.4

 

55.4

 

toggle chart

Trading volume (in CHF mn)

 

1 644.9

 

2 315.6

 

2 004.2

 

2 610.7

 

2 864.7

 

toggle chart

Profit/(loss) (in CHF mn)

 

141.1

 

691.2

 

677.4

 

(471.3)

 

687.5

 

toggle chart

Closing price at the end of the period in CHF

 

84.15

 

74.15

 

66.25

 

58.40

 

64.55

 

toggle chart

Closing price (G) at the end of the period in EUR

 

77.70

 

68.00

 

61.40

 

52.00

 

55.68

 

toggle chart

Closing price (I) at the end of the period in EUR

 

77.95

 

68.50

 

61.00

 

52.00

 

55.20

 

toggle chart

Stock performance (incl. distributions) 1)

 

18.2%

 

19.3%

 

18.5%

 

(5.2%)

 

22.9%

 

toggle chart

High/low share price in CHF

 

92.20/73.40

 

74.70/45.44

 

73.20/59.35

 

74.10/56.10

 

67.80/52.10

 

toggle chart

High/low share price in EUR

 

86.20/67.80

 

69.00/43.04

 

64.70/52.10

 

64.80/48.60

 

59.10/48.42

 

toggle chart

Premium/(discount) (annual average)

 

17.4%

 

9.2%

 

11.8%

 

9.7%

 

(2.5%)

 

toggle chart

Dividend in CHF

 

N.A.

 

3.60

 

3.40

 

3.05

 

3.30

 

toggle chart

Degree of investment (quarterly figures)

 

107.8%

 

106.8%

 

109.1%

 

108.4%

 

103.1%

 

toggle chart

Total Expense Ratio (TER) p.a. 2)

 

1.23%

 

1.25%

 

1.26%

 

1.25%

 

1.27%

 

toggle chart

1 All figures in CHF %, total return-methodology

2 Based on market capitalization

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer